Company intelligence / Profile preview
Lifordi Immunotherapeutics
Burlington, Massachusetts, United Stateslifordi.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lifordi's lead candidate LFD-200 has demonstrated efficacy in multiple preclinical disease models, including a rheumatoid arthritis mouse model. In non-human primates, LFD-200 showed a relatively low serum half-life of 14 hours, but its payload is retained in immune organs for longer periods, supporting reduced systemic toxicity and lower dosing for targeted activity in immune organs.[7]
- Therapeutic areas
- Immunology
- Modalities
- Antibody-drug conjugates (ADCs)Antibody Fragment-Drug Conjugates (FDCs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Lifordi Immunotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lifordi Immunotherapeutics.